MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”), an emerging biomedical device company focused on commercializing innovative companion animal medical and therapeutic devices, today announced the launch of two new websites; the first presenting the company and the second the current Spryng™ product from PetVivo with OsteoCushion™ technology. Each website went live on March 4, 2022. The new websites offer a clean, modern design, easy navigation, and helpful tools and resources for anyone to learn more about PetVivo and its products. Through this launch and the future growth of these new corporate and product websites, PetVivo strives as an industry leader to provide consistent and relevant information, news and other resources that you can use daily.
“We are excited to launch these new websites and are confident that they will serve as a useful informational portal for pet owners, veterinarians and others seeking to better understand PetVivo, our innovative product, Spryng, and everything what we have to offer,” said John Lai, Managing Director of PetVivo Holdings, Inc. “I believe these new websites align well with our company’s vision for growth and expansion at the future.
The goal of the new look and feel of the PetVivo corporate website is to better provide innovative resources and information to veterinarians, pet owners, as well as existing and potential investors, covering product information , press releases, product information and other general company information. . The website will highlight all the tools and resources available at the click of a button and make it clear that PetVivo is on the cutting edge of industry trends and technology. The new PetVivo corporate website can be accessed at www.petvivo.com
Additionally, the purpose behind launching the Spryng product website is to better provide product educational information for veterinarians as well as pet owners. The website will feature comprehensive information regarding the product composition and use of Spryng, case studies and scientific information demonstrating the benefits of the product, and a portal for ordering and purchasing Spryng. The Spryng product website can be accessed at www.sprynghealth.com.
PetVivo’s innovative therapeutic product, Spryng with OsteoCushion Technology, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from natural components, collagen and elastin. OsteoCushion technology provides both natural joint support to replace and/or reinforce missing and damaged cartilage, as well as a natural scaffold to help treat tissue defects. These attributes provide an excellent solution for managing lameness and joint conditions, such as osteoarthritis, for pets in a simple in-clinic treatment.
For more information about PetVivo Holdings, Inc., please contact [email protected] or visit https://petvivo.com/
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on manufacturing, marketing and licensing of innovative medical and therapeutic devices for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient manner. A key part of this strategy is accelerating the revenue timeline for veterinary medical devices, which enter the market much earlier than more strictly regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The company’s lead product, SPRYNG, a veterinarian-administered intra-articular injection for the treatment of lameness and other joint conditions, including osteoarthritis, in dogs and horses, is currently available for sale. commercial to veterinarians.
John Lai, CEO PetVivo Holdings, Inc. Email: [email protected] (952) 405-6216
Forward-looking business statements:
The foregoing information may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including, without limitation, the Company’s proposed development and business timelines, and can be identified by the use of words such as “may”, “will”, “expect”, “project”, “estimate”, “anticipate”, “plan”, “believe”, “potential”, “should”, “continue” or negative versions of these words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on currently available information of the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could affect significantly the current plans. Risks relating to the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021 and in other periodic and routine reports filed with the Securities and Exchange Commission. . The Company is under no obligation to update or change its forward-looking statements, and expressly disclaims any such obligation, whether as a result of new information, future events or otherwise.
Copyright 2022 GlobeNewswire, Inc.